NasdaqGS - Nasdaq Real Time Price USD

Alumis Inc. (ALMS)

4.8800

-1.0700

(-17.98%)

At close: May 20 at 4:00:01 PM EDT

5.0988

+0.22

+(4.48%)

After hours: May 20 at 7:29:49 PM EDT

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones. “We’re seeing strong momentum across our development programs, with our t

GlobeNewswire 6 days ago

ALMS
-17.98%
Alumis Stockholders Approve Merger with ACELYRIN

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (Nasdaq: SLRN) at its Special Meeting of Stockholders. Mart

GlobeNewswire 7 days ago

ALMS
-17.98%

SLRN
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company’s special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company’s merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN

GlobeNewswire 7 days ago

ALMS
-17.98%

SLRN
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction TodayACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that ACELYRIN stockholders

GlobeNewswire 14 days ago

SLRN

ALMS
-17.98%
Acelyrin urges stockholders to vote for proposed merger with Alumis

ACELYRIN (SLRN) reiterated its confidence that the proposed combination with Alumis (ALMS) is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the independent transaction committee, said, “The ACELYRIN Board and management team are confident that the proposed merger with Alumis represents the most value-maximizing path forward for our company’s stockholders. The agreement with Alumis fo

TipRanks 18 days ago

ALMS
-17.98%

SLRN
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc. (Nasdaq: ALMS) is the best path forward and the most value-maxi

GlobeNewswire 19 days ago

ALMS
-17.98%

SLRN
Acelyrin should liquidate instead of merging with Alumis, investor says

Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more upside to a liquidation than Acelyrin’s planned merger.

BioPharma Dive 21 days ago

SLRN

ALMS
-17.98%
Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger an

GlobeNewswire 29 days ago

ALMS
-17.98%

SLRN
Insider Buying: Alumis Independent Director Bought US$130k Of Shares

Potential Alumis Inc. ( NASDAQ:ALMS ) shareholders may wish to note that the Independent Director, Alan Colowick...

Simply Wall St. last month

ALMS
-17.98%
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of pa

GlobeNewswire last month

SLRN

ALMS
-17.98%
Alumis and Kaken sign agreement in Japan to develop ESK-001

Kaken will pay Alumis $40m in upfront and near-term co-development payments from 2025 to 2026.

Pharmaceutical Technology last month

ALMS
-17.98%
Sector Update: Health Care Stocks Steady Premarket Tuesday

Health care stocks were steady premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) sl

PREMIUM
MT Newswires last month

ALMS
-17.98%
Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

Alumis (ALMS) and Kaken Pharmaceutical have struck a collaboration and licensing agreement to develo

PREMIUM
MT Newswires last month

ALMS
-17.98%
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis’ ESK-001 and leverages Kaken’s regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointest

GlobeNewswire last month

ALMS
-17.98%
Why Alumis Inc. (ALMS) Went Down On Thursday?

We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where Alumis Inc. (NASDAQ:ALMS) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on Thursday, erasing gains from the previous trading day that was buoyed by the Federal Reserve’s decision to […]

Insider Monkey last month

ALMS
-17.98%

^GSPC
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 – – Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 – – Announced merger agreement with ACE

GlobeNewswire 2 months ago

ALMS
-17.98%
Alumis to Present at Leerink's 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40

GlobeNewswire 2 months ago

ALMS
-17.98%
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupusPhase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0ESK-001 was generally well-tolerated at one year, with no new safety findingsData further support ESK-001’s potential to offer a highly differentiated and best-in-class treatment opti

GlobeNewswire 2 months ago

ALMS
-17.98%
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of A

GlobeNewswire 2 months ago

ALMS
-17.98%

SLRN
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “Alumis an

GlobeNewswire 2 months ago

ALMS
-17.98%

SLRN

Performance Overview

Return	ALMS	S&P 500 (^GSPC)
YTD	-37.91%	+1.00%
1-Year	-63.85%	+11.91%
3-Year	-63.85%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alumis Inc. (ALMS)

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

Acelyrin urges stockholders to vote for proposed merger with Alumis

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Acelyrin should liquidate instead of merging with Alumis, investor says

Alumis and ACELYRIN Announce Amended Merger Agreement

Insider Buying: Alumis Independent Director Bought US$130k Of Shares

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken sign agreement in Japan to develop ESK-001

Sector Update: Health Care Stocks Steady Premarket Tuesday

Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Why Alumis Inc. (ALMS) Went Down On Thursday?

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Performance Overview